<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01838408</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00008184</org_study_id>
    <nct_id>NCT01838408</nct_id>
  </id_info>
  <brief_title>Evaluation of Proposed EZ2go Complete Bowel Cleansing System</brief_title>
  <official_title>Randomized, Single Blinded Study of Proposed EZ2go Complete Bowel Cleansing System: Evaluation of Its Safety, Efficacy and Patient Tolerance Compared to LOSO Prep, an Over the Counter Laxative Kit for Colonoscopy Bowel Preparation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Borland-Groover Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Valley Medical Products, LLC is paying for the study and is the sponsor. The form would not go through with this listed.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Borland-Groover Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to provide safety and efficacy data comparable to available over-the-counter&#xD;
      bowel preparations prior to colonoscopy. While there are many bowel preparations available,&#xD;
      most of them remain expensive and require prescription from a health provider. The&#xD;
      investigators believe EZ2go Complete will provide a non-inferior colon cleansing in a more&#xD;
      accessible way (over-the-counter).&#xD;
&#xD;
      To accomplish this goal, the investigators decided to evaluate the proposed EZ2go combination&#xD;
      versus currently available over-the-counter bowel preparations. The investigators believe the&#xD;
      EZ2go kit will not be inferior to current FDA approved over-the-counter bowel preparations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of Efficacy</measure>
    <time_frame>24 hours</time_frame>
    <description>The primary end point is efficacy of colonoscopy preparation measured by the Ottawa scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the safety</measure>
    <time_frame>2 weeks</time_frame>
    <description>A basic metabolic panel will be drawn at baseline and after the bowel preparation is complete to evaluate for any electrolyte and renal disturbances.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">185</enrollment>
  <condition>Screening Colonoscopy</condition>
  <condition>Surveillance Colonoscopy</condition>
  <condition>Colonoscopy</condition>
  <arm_group>
    <arm_group_label>EZ2go Complete</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EZ2go complete: Peg 3350, Magnesium Citrate and Simethicone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LoSo Prep ™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LoSo Prep ™: Magnesium citrate and Bisacodyl</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ez2go Complete</intervention_name>
    <description>EZ2Go Complete</description>
    <arm_group_label>EZ2go Complete</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>LoSo Prep</intervention_name>
    <description>LoSo Prep ™ Magnesium Citrate plus Bisacodyl Kit Study Arm</description>
    <arm_group_label>LoSo Prep ™</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients referred for routine colorectal cancer screening or surveillance colonoscopy&#xD;
             examinations.&#xD;
&#xD;
          -  Male and Female participants 18 years of age and older.&#xD;
&#xD;
          -  Female participants who are not pregnant or planning to become pregnant within the&#xD;
             next 90 days, or are sterile or of non-childbearing potential.&#xD;
&#xD;
          -  Negative urine test at the screening visit.&#xD;
&#xD;
          -  Subject is able to read and understand the informed consent form and signs the&#xD;
             informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to any of the bowel preparations being used in the study.&#xD;
&#xD;
          -  Unable/unwilling to fill out patient questionnaires following procedure.&#xD;
&#xD;
          -  Pregnant or lactating.&#xD;
&#xD;
          -  Unwilling to perform indicated lab work.&#xD;
&#xD;
          -  Lab results that would indicate stage 4-5 chronic kidney disease (GFR &lt;30MI/min1.73&#xD;
             m2).&#xD;
&#xD;
          -  Personal history of colorectal cancer.&#xD;
&#xD;
          -  Personal history of colorectal or small bowel surgery.&#xD;
&#xD;
          -  Participants have any condition that, in the investigators opinion, could interfere&#xD;
             with the participation and completion of this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Borland-Groover Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.borland-groover.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>April 16, 2013</study_first_submitted>
  <study_first_submitted_qc>April 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2013</study_first_posted>
  <last_update_submitted>January 26, 2015</last_update_submitted>
  <last_update_submitted_qc>January 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>screening colonoscopy</keyword>
  <keyword>surveillance colonoscopy</keyword>
  <keyword>colonoscopy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

